News - Velcade, pomalidomide

Filter

Current filters:

Velcadepomalidomide

Popular Filters

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma

12-11-2013

In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

Celgene's pomalidomide meets primary endpoint in multiple myeloma

05-09-2013

US biotech major Celgene (Nasdaq: CELG) announced that positive updated results from MM-003, a Phase…

BiotechnologyCelgeneImnovidOncologypomalidomidePomalystResearch

Pomalidomide Celgene OKed in Europe

09-08-2013

The European Commission has granted approval for US biotech firm Celgene's (Nasdaq: CELG) Pomalidomide…

BiotechnologyCelgeneEuropeImnovidOncologypomalidomidePomalidomide CelgeneRegulation

EU backs wider use of Velcade

09-08-2013

The European Commission has approved the use of Johnson & Johnson (NYSE: JNJ) European subsidiary Janssen-Cilag's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma

08-04-2013

Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

FDA approves Celgene's Pomalyst for advanced multiple myeloma

11-02-2013

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Pomalyst…

BiotechnologyCelgeneNorth AmericaOncologypomalidomidePomalystRegulation

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Celgene's pomalidomide meets MM-003 study endpoints

23-10-2012

US biotech firm Celgene's (Nasdaq: CELG) European subsidiary yesterday revealed that its phase III, multi-center,…

BiotechnologyCelgeneOncologypomalidomideResearch

VentiRx collaborates with Celgene on cancer drug candidate; pomalidomide update

05-10-2012

VentiRx Pharmaceuticals, a privately held US biopharmaceutical company dedicated to the development of…

BiotechnologyCelgeneLicensingNorth AmericaOncologyPharmaceuticalpomalidomideRegulationVentiRx PharmaceuticalsVTX-2337

Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine

21-09-2012

US biotech firm Celgene (Nasdaq: CELG) says that the US Food and Drug Administration's Oncologic Drugs…

Asia-PacificBiotechnologyCelgeneLundbeckNeurologicalNorth AmericaOncologyPharmaceuticalpomalidomideRegulationvortioxetine

First-line multiple myeloma patient share in Europe is variable by country

29-08-2012

Despite the considerable heterogeneity across different European countries, surveyed hematologist-oncologists…

AlkeranBiotechnologyCelgeneGlaxoSmithKlineHealthcareJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalThalomidVelcade

Johnson & Johnson pulls EU submission for Velcade use in NHL

05-07-2012

The European Medicines Agency has been formally notified by US health care giant Johnson & Johnson's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Celgene slumps as it pulls new EU indication filing for Revlimid

22-06-2012

Celgene International, the European subsidiary of USA-based Celgene Corp (Nasdaq: CELG), has provided…

BiotechnologyCelgeneEuropeFinancialOncologyPharmaceuticalpomalidomideRegulationRevlimid

5.6% annual growth forecast for multiple myeloma drug market to 2020

21-12-2011

Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and…

CelgeneGlobalJanssen-CilagMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Takeda’s Millennium files two sNDAs for Velcade with US FDA

28-04-2011

Japan’s largest drugmaker, Takeda Pharmaceutical (TSE: 4502), together with its US oncology subsidiary…

BiotechnologyMillennium PharmaceuticalsNorth AmericaOncologyPharmaceuticalRegulationTakeda PharmaceuticalsVelcade

Back to top